Peter Attia· MD
the nih because they wrote a summary of luvoxamine where they described its benefit and impact on reducing hospitalizations and survival and concluded at the end of it that there was insufficient data to recommend it
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
the nih because they wrote a summary of luvoxamine where they described its benefit and impact on reducing hospitalizations and survival and concluded at the end of it that there was insufficient data to recommend it
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.